Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people taking Mounjaro for the first time inject the 2.5mg starter dose and then wait. The first week is largely about your body adjusting to a new medicine, not about dramatic weight loss. Some mild nausea, a reduced appetite, and a sense of fullness after smaller meals are all typical early signs that tirzepatide is doing its job. Here is what the first week genuinely looks like, based on how the medicine works and what the clinical evidence tells us — because the gap between expectation and reality is where most of the early anxiety lives. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber reviews every consultation before it is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Your first Mounjaro pen contains four weekly doses at 2.5mg. You inject once, into the abdomen, thigh, or upper arm, then put the pen back in the fridge. That is the entirety of week one's active task.
The hours that follow are where people's experiences split. Some feel little different on day one. Others notice a dull nausea by the evening, sometimes a mild headache or tiredness. Neither pattern is wrong. Gastric emptying slows as tirzepatide takes effect, and for some people that shift is more noticeable than for others. Keeping meals small, eating slowly, and drinking water steadily throughout the day makes a real difference to how the first 48 hours feel. The practical habits that support Mounjaro are worth reading before your first injection, not after.
One misconception worth letting go early: nausea does not mean the medicine is harming you. It is a predictable consequence of slowed gastric emptying, it tends to be worst in the first few days, and for most people it settles well before the next dose is due. If it is severe or persistent, that is a conversation for your prescriber, not something to push through alone.
By the middle of the first week, most people start to notice the appetite effect more clearly. Meals feel satisfying sooner. The pull toward snacking between meals is quieter. This is tirzepatide acting on both the GIP and GLP-1 pathways, a dual mechanism that no other licensed UK weight-loss injection shares, as the Mounjaro overview explains in more detail.
Energy can dip during these days. That is partly because you are eating less, partly because your digestive system is working differently. Protein at each meal and consistent hydration help significantly. Some people feel fine. A smaller group feels tired enough that they would rather inject on a Friday than a Monday, timing the dose around your week is a small practical adjustment worth raising with your prescriber.
On the question of weight: some people see a small shift by day five, often partly water, partly the result of eating less. Others see nothing yet. Both are normal at this stage. If the scales are moving is genuinely less useful a question right now than how are you tolerating the medicine.
By the time your second dose is due, the first week's side effects have usually eased. Appetite suppression often feels more consistent by now rather than coming in waves. This is a useful baseline: whatever you are experiencing at day seven is roughly what a dose-increase week will feel like again at a lower intensity.
Most people have not lost a significant amount of weight after seven days. That is not a problem with the medicine; it is how it works. The SURMOUNT-1 trial, published in the New England Journal of Medicine, found average weight reductions of around 20–21% at the highest dose over 72 weeks, the emphasis being on 72 weeks, not 72 hours. What the first week does is establish tolerability and begin the appetite recalibration that drives those longer-term results. More on what first-week results typically look like is worth reading alongside this.
If weight loss feels slow in the early weeks, that is a very common experience. The page on not losing weight in week one covers the reasons in more depth. And if you are curious how the first-week experience compares with the broader tirzepatide picture, the first week on tirzepatide gives useful context.
The most common effects in the first week are gastrointestinal: nausea, constipation or loose stools, indigestion, and a feeling of fullness that can verge on uncomfortable if you eat too quickly. These are well-documented in the NHS's patient information on tirzepatide and are considered part of the normal dose-adjustment period.
What should prompt you to seek medical help rather than wait it out: severe or persistent stomach pain, especially pain that radiates toward the back. This can occasionally signal pancreatitis, which is an infrequent but serious side effect of GLP-1 and dual-agonist medicines. Dehydration from persistent vomiting or diarrhoea also warrants a call. For anything that concerns you, your prescriber is the right first contact, and at nume, aftercare is available seven days a week.
The cost of treatment, including what a transparent private price should cover, is something many people research alongside the clinical questions. The Mounjaro cost page covers what to look for and what legitimate pricing typically includes. For a fuller picture of the timeline to meaningful results, that page is the natural next step after this one.
If you have questions before starting, or want to understand whether Mounjaro is clinically suitable for you, speak to our prescribers via a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.